Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer
1002.3500 14.70 (1.49%)
NSE Oct 20, 2025 15:31 PM
Volume: 820.1K
 

1002.35
1.49%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Q3FY19 results were stronger-than-expected on all fronts due to strong US growth. Revenues grew 9.8% YoY to | 3578 crore (I-direct estimate: | 3222 crore) due to 22.1%, 46.5% YoY, QoQ growth in the US to | 1934 crore (I-direct estimate: | 1563.4 crore) EBITDA margins contracted 234 bps to 23.5% (I-direct estimate: 23.3%), due to an adverse product mix. EBITDA remained flat at | 840 crore but higher than I-direct estimate of | 750.7 crore...
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended